RNXT
RenovoRx, Inc.
There isn't enough reported data to score RNXT yet.
RNXT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
RNXT's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
RNXT PE Valuation
RNXT has no meaningful PE right now: it lost money over the past year.
RNXT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect RNXT's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
RNXT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.31 | +$0.06 |
| Q2 2026 | -$0.31 | +$0.08 |
| Q1 2026 | -$0.33 | +$0.08 |
| Q4 2025 | -$0.32 | +$0.08 |
| Q3 2025 | -$0.37 | +$0.18 |
| Q2 2025 | -$0.39 | +$0.19 |
| Q1 2025 | -$0.41 | +$0.29 |
| Q4 2024 | -$0.40 | +$0.59 |
RNXT is still losing money, but far less than before: $0.31 per share over the past year, against $1.13 at its worst in early 2023.
RNXT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | +301% |
| Q2 2026 | $909K | +115% |
| Q1 2026 | $563K | +186% |
RNXT's revenue has grown year over year for seven quarters in a row: $1M last quarter, up 301% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -304% | +900 points |
| Q2 2026 | -368% | +266 points |
| Q1 2026 | -616% | +963 points |
| Q4 2025 | -1480% | N/A |
| Q3 2025 | -1203% | N/A |
| Q2 2025 | -635% | N/A |
| Q1 2025 | -1579% | N/A |
RNXT's operating margin was −304% last quarter, up 899 points from the same quarter a year ago.
RNXT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.6M | -$288K |
| Q2 2026 | -$2.9M | -$636K |
| Q1 2026 | -$3.7M | -$326K |
| Q3 2025 | -$2.3M | -$76K |
| Q2 2025 | -$2.3M | -$5K |
| Q1 2025 | -$3.4M | -$1.2M |
| Q3 2024 | -$2.2M | +$534K |
| Q2 2024 | -$2.3M | +$474K |
RNXT has burned cash in almost every quarter: −$12M over the past year, against −$10M the year before.
RNXT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +896K shares |
| 1 year | +32% | +11.6M shares |
| 3 years | +432% | +39.1M shares |
| 5 years | +187% | +31.4M shares |
RNXT has 48M diluted shares, up 32% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RNXT Net Leverage
RNXT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RNXT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.5 | Neutral |
| Stochastic | 19.2 | Oversold |
RNXT's weekly RSI is 48 (neutral) and its Stochastic is 19 (oversold).
RNXT PE vs Healthcare Sector
RNXT has no meaningful PE right now: it lost money over the past year.
RNXT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.32 | 12% below |
| 20 week MA | $1.32 | 12% below |
| 50 week MA | $1.09 | 6.4% above |
| 100 week MA | $1.12 | 3.6% above |
| 200 week MA | $1.40 | 17% below |
RNXT's trend is mixed: it's above two of its five weekly moving averages, and 17% below its 200-week average.
RNXT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $7.71 | $5.09 | -34% |
| 2022 | $5.09 | $1.97 | -61% |
| 2023 | $1.97 | $2.29 | +16% |
| 2024 | $2.29 | $1.30 | -43% |
| 2025 | $1.30 | $0.85 | -35% |
| 2026 YTD | $0.85 | $1.16 | +36% |
RNXT is up 36% so far in 2026, after finishing lower in four of the previous five years.